Search academic texts

Information × Registration Number 0225U001208, (0123U100713) , R & D reports Title Improving the results of conservative treatment of breast cancer patients with low or negative HER2/neu status based on optimization and individualization of therapy methods popup.stage_title Вивчити вплив хемокіну CCR5 та експресії TKS4 і PDL-1 на терміни до прогресування захворювання після курсу стандартної НАХТ у хворих на рак грудної залози з низьким або негативним статусом HER2/neu. Head Lialkin Serhii A., д.мед.н. Registration Date 27-01-2025 Organization National Cancer Institute popup.description1 To increase the effectiveness of treatment of breast cancer patients with low or negative HER 2/neu status after standard preoperative chemotherapy by determining the level of chemokines in peripheral blood and taking into account the characteristics of the immune tumor microenvironment. popup.description2 The object of the study was 95 patients with breast cancer, 46 patients were Her2/neu negative, 49 with Her2/neu low status. The aim of the work was to increase the effectiveness of treatment of patients with breast cancer with low or negative HER 2/neu status after standard preoperative chemotherapy by determining the level of chemokines in peripheral blood and taking into account the characteristics of the immune tumor microenvironment. Research methods and equipment: clinical, laboratory, instrumental, statistical; ultrasound device “Aloca”, hematological analyzer VS-3000, biochemical analyzer “Vitros”, photoelectron multiplier FEU-130, photon counter HLMC-01 with power supply B5-24A (Meridian, Ukraine), permanent magnet with electric motor. In patients with Her2/neu low-grade HCC who received NPCT, a statistically significant increase in stromal CD8+ lymphocytes after the completion of NPCT (p = 0.01) and a decrease in the level of CD4+ intratumoral lymphocytes were found. These results indicate the ability of cytostatic therapy to increase the immunogenicity of HCC with low Her2/neu expression. The presence of a relationship between the effectiveness of NPCT and the level of stromal CD4+ lymphocytes and the level of tumor-infiltrating lymphocytes in the trepanobiopsy material before the start of NPCT in patients with Her2/neu low-grade HCC was proven. It was studied that an increase in the level of PIL at the time of diagnosis significantly reduces the chances of not achieving a pronounced morphological response (OR = 0.3 p = 0.02). A logistic model for predicting the risk of not achieving a pronounced morphological response after NPHT among patients with Her2/neu low-grade RGZ was developed, which takes into account the level of stromal CD4+ lymphocytes and the level of PIL. A stand was developed for experimental study of mechanoluminescence of Walker-256 carcinosarcoma cells with a magnetic Fe3O4-Au nanocomplex. Product Description popup.authors Aleksyk Olena M. Kriachok Iryna A. Rykhalskyi Oleksandr Yu. Rudiuk Tymur O. Tytorenko Iryna B. Shudrak Pavlo A. popup.nrat_date 2025-01-27 Close